Nikon, Riken, Others To Join For Mass-Production Of iPS Cell Treatments
This article was originally published in PharmAsia News
Executive Summary
Nikon, the Riken Institute and several Japan institutions plan a joint effort for mass production of induced pluripotent stem cells in fiscal year 2017 as one way to reduce the cost of regenerative treatments.